Furthermore, our study also indicated that attenuation of aortic VSMC stiffening by pharmacological inhibition, such as the inhibitors of SRF/myocardin, can serves as a promising therapeutic target to correct aortic stiffening not only in hypertension, but also in other age-related vascular diseases. This evidence concerns the gene SRF and hypertensive disorder.